eyenovia-logo 3

2017 News Releases

Keyword Search
2018 | 2017 | 2016 | 2015
Eyenovia Publication of EYE 102 Phase II Results Demonstrates Strong Pharmacodynamic Effect, Tolerability and Reduced Systemic Exposure of High- Precision Micro-dosing compared to Conventional Eyedroppers
Results published online ahead of print in peer-reviewed publication Therapeutic DeliveryEYE 102 marks second Phase II study demonstrating benefit of micro-therapeutic approach NEW YORK--(BUSINESS WIRE)--Eyenovia Inc., a clinical-stage ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of potential first-in-class micro-therapeutics for the eye, today announced that the positive results of its EYE 102 Phase II study have been published online ahead of ... 

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017     +1 (917) 289-1117

[email protected]